

EFS

Applicants : Betty A. Diamond and Bruce T. Volpe

Appn. No. : 10/574,994

Filing Date: January 31, 2007

Reply filed September 20, 2010

Page 2 of 8

Amendments to the Claims:

Please amend Claims 23 and 46 as set forth below.

1-22. (Canceled)

23. (Currently amended) A method of inhibiting progression of cognitive dysfunction in a mammal diagnosed as exhibiting ~~or as being at risk for~~ lupus-induced cognitive dysfunction, the method comprising administering to the mammal an amount of an agent effective to inhibit progression of cognitive dysfunction in the mammal, ~~treating the mammal with an agent that prevents binding of an anti-ds-DNA antibody to an NR2 subunit of an N-methyl-D-aspartate (NMDA) receptor of a neuron in the brain,~~ wherein the agent comprises amino acid sequence X1-Trp-X1-Tyr-X2 (SEQ ID NO:1), wherein each of X1 independently represents Asp or Glu, and X2 represents Gly or Ser.

24. (Canceled)

25. (Original) The method of claim 23, wherein the neuron is in the hippocampus.

26-44. (Canceled)

45. (Previously presented) The method of claim 23, wherein the agent is administered to the brain of the mammal.

EFS

Applicants : Betty A. Diamond and Bruce T. Volpe

Appn. No. : 10/574,994

Filing Date: January 31, 2007

Reply filed September 20, 2010

Page 3 of 8

46. (Currently amended) A method of determining whether a patient may be ~~is~~ at risk for lupus-induced cognitive dysfunction, the method comprising determining whether the patient has anti-NR2 antibodies in a blood or cerebrospinal fluid sample of the patient, wherein the presence of anti-NR2 antibodies in the sample indicates that the patient may be ~~is~~ at risk for lupus-induced cognitive dysfunction. ~~, and if the patient is at risk for lupus induced cognitive dysfunction, treating the patient with an agent that prevents binding of an anti-NR2 antibody to an NR2 subunit of an N-methyl-D-aspartate (NMDA) receptor of a neuron in the brain, wherein the agent comprises amino acid sequence X1-Trp-X1-Tyr-X2 (SEQ ID NO:1), wherein each of X1 independently represents Asp or Glu, and X2 represents Gly or Ser.~~

47. (Previously presented) The method of claim 46, wherein the cerebrospinal fluid is tested for the presence of anti-NR2 antibodies.

48. (Previously presented) The method of claim 46, wherein the blood is tested for the presence of anti-NR2 antibodies.

49-50. (Canceled)

51. (Previously presented) The method of claim 46, wherein the agent comprises Asp-Trp-Glu-Tyr-Ser (SEQ ID NO:1).

52-53. (Canceled)

EFS

Applicants : Betty A. Diamond and Bruce T. Volpe

Appn. No. : 10/574,994

Filing Date: January 31, 2007

Reply filed September 20, 2010

Page 4 of 8

54. (Withdrawn) The method of claim 23, wherein the agent comprises D-amino acids.

55. (Previously presented) The method of claim 23, wherein the agent comprises Asp-Trp-Glu-Tyr-Ser (SEQ ID NO:1).

56. (Previously presented) The method of claim 23, where the mammal is diagnosed as exhibiting lupus-induced cognitive dysfunction.

57. (Previously presented) The method of claim 23, where the mammal is diagnosed as being at risk for lupus-induced cognitive dysfunction.